Ureteral endometriosis post-hysterectomy for adenomyosis: a case report and literature review

Objective To explore the necessity of long-term pharmacological management following total hysterectomy for adenomyosis.

A case of ureteral endometriosis identified over one year after laparoscopic total hysterectomy and bilateral salpingectomy for adenomyosis was retrospectively analyzed. Clinical data were reviewed, and related literature was summarized for discussion.

The patient underwent laparoscopic total hysterectomy and bilateral salpingectomy at our hospital more than one year prior because of adenomyosis. No pharmacological treatment was provided postsurgery. One year later, the patient presented with right lumbar discomfort. Imaging revealed hydronephrosis of the right kidney and dilation of the right ureter, leading to a diagnosis of right ureteral endometriosis. Laparoscopic excision of the ureteral endometriotic lesion was performed. Pathology confirmed right ureteral endometriosis with glandular cystic expansion. Postsurgery, the patient was treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy (3.6 mg of goserelin via subcutaneous injection every 28 days for a total of six cycles). Treatment is ongoing. Follow-up ultrasound revealed no abnormalities in the kidneys or ureters, and no recurrence was observed during the five months of follow-up.

Adenomyosis is often associated with deep endometriosis. Even if no evident deep pelvic endometriosis is identified during total hysterectomy, long-term pharmacological management postsurgery may still be necessary. This approach can reduce the incidence of deep endometriosis in organs such as the bladder, ureters, and intestines.

Adenomyosis, Ureteral endometriosis, Hysterectomy, Case report Ureteral endometriosis post-hysterectomy for adenomyosis: a case report and literature review Yujuan Lu1* and Yu Wang1 Page 2 of 7 Lu and Wang BMC Urology (2025) 25:164

Endometriosis (EM) refers to the presence, growth, and infiltration of endometrial tissue (glands and stroma) outside the uterine cavity, causing symptoms such as dysmenorrhea, pelvic pain, and infertility. Its prevalence among women of reproductive age ranges from 5 to 15% [1]. Adenomyosis (AM), considered a distinct but related condition, involves the invasion of endometrial tissue into the myometrium and has a prevalence of up to 70% [2]. AM and EM are both estrogen-dependent conditions, but they differ in pathophysiology and clinical presenta - tion. AM is characterized by the infiltration of endome - trial glands and stroma into the myometrium, typically leading to uterine enlargement, heavy menstrual bleed - ing, and dysmenorrhea [ 3]. In contrast, EM involves the ectopic growth of endometrial tissue outside the uterus— such as in the ovaries, peritoneum, or deep pelvic struc - tures—and commonly presents with chronic pelvic pain and infertility [4]. Despite these differences, both are considered chronic inflammatory diseases that may share a common origin. EM can lead to debilitating symptoms such as cyclic pel - vic pain, infertility, and bowel or urinary dysfunction, significantly impairing quality of life and psychosocial well-being. Studies have reported that up to 30–50% of women with EM may experience infertility, and many suffer from years of delayed diagnosis due to overlapping symptoms with other gynecologic or gastrointestinal dis - orders [5]. Urinary tract endometriosis, including ureteral involve- ment, is a rare subtype of deep infiltrating endometriosis (DIE), with ureteral cases comprising approximately 10% of urinary tract involvement [6]. Its occurrence after hys- terectomy for AM is particularly rare. Ureteral endometriosis (UE), a rare manifestation, occurs in only 0.1–1.7% of EM cases [ 7]. It is often sec - ondary to other forms of endometriosis, with 52–68% of cases associated with ovarian endometriotic cysts (chocolate cysts) and 10–56% involving lesions affecting the uterosacral ligaments, cardinal ligaments, and rec - tovaginal septum, among other paracervical structures. Isolated or solitary UE is rare [ 8]. This report presents a case of UE identified more than one year after total hys - terectomy for AM. Case presentation A 48-year-old female was admitted on March 12, 2023, due to moderate anemia and an ultrasound finding of uterine enlargement. The patient reported dysmenor - rhea and menorrhagia but no dyspareunia. Laboratory tests revealed a hemoglobin (Hb) level of 69  g/L and a CA125 level of 53.2 U/ml. Pelvic ultrasound revealed a 7.1 × 4.8 × 7.0  cm mixed echogenic mass with an “onion-skin” appearance, as shown in Fig. 1. She was diagnosed with adenomyosis and moderate anemia and underwent laparoscopic total hysterectomy and bilateral salpingectomy. Intraoperative exploration of the pelvic cavity revealed no signs of endometriotic lesions. Postop- erative pathology revealed adenomyosis combined with leiomyoma. The surgery was successful, and the post - operative recovery was smooth. However, no long-term pharmacological management was provided after the surgery. On April 25, 2024, the patient was admitted to the Urology Department due to right lumbar discomfort. CT imaging revealed a soft tissue density nodule in the distal right ureter near the entrance to the bladder, measuring approximately 24.5 × 16.5 × 18 mm, with unclear margins and associated hydronephrosis and dilation of the ure - ter proximal to the lesion (Fig. 2). On April 28, 2024, the patient underwent a right ureteral biopsy and transure - thral right ureteral stent placement. Intraoperatively, the ureteral mucosa appeared smooth, with no visible neo - plasms. Postoperative pathology revealed proliferative fibrous connective tissue. A multidisciplinary consultation involving the Gyne - cology Department revealed the patient’s history of ade - nomyosis, raising suspicion of ureteral endometriosis. After discussion with the patient and her family, she was admitted to the Gynecology Department on July 12, 2024. MRI revealed an abnormal nodular signal in the pelvic segment of the right ureter near the bladder, suggesting a possible neoplastic lesion. On July 15, 2024, the patient underwent laparoscopic excision for deep ureteral endo - metriosis and ureterolysis. The surgery was successful, and the postoperative recovery was uneventful. Pathol - ogy confirmed ureteral endometriosis with glandular cystic expansion (Fig. 3). There were no significant diag - nostic challenges encountered in this case. The patient was subsequently treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy (3.6 mg of goserelin via subcutaneous injection every 28 days, six doses). The patient adhered well to the prescribed GnRH-a therapy and reported no discomfort or adverse effects during the treatment course. She also expressed satisfaction with the treatment out - come and reported improvement in symptoms following the intervention. On August 15, 2024, the patient underwent removal of the right ureteral stent via ureteroscopy in the Urol - ogy Department. Intraoperatively, no neoplasms, fistulas, or strictures were observed in the ureter. The procedure was successful. Follow-up ultrasound five months later revealed no abnormalities in the kidneys, ureters, or bladder. The patient has remained under follow-up, and no recurrence has been detected to date. Page 3 of 7 Lu and Wang BMC Urology (2025) 25:164 Fig. 2 CT image of ureteral endometriosis Fig. 1 Vaginal ultrasound image of the uterus Page 4 of 7 Lu and Wang BMC Urology (2025) 25:164 To clarify the diagnostic and treatment sequence, a chronological summary of the patient’s clinical course is presented in Table 1. This timeline outlines the key symp- toms, surgical procedures, departmental transitions, and clinical outcomes from March 2023 through August 2024. Additional narrative details are provided below.

UE refers to the implantation of active endometrial tis - sue around or directly infiltrating the ureter. Its onset is insidious, with 30% of patients presenting no clinical symptoms, whereas others may experience nonspecific symptoms such as dysmenorrhea, dyspareunia, or non - menstrual pelvic pain [ 9]. These characteristics often lead to diagnostic challenges and delays, potentially caus- ing silent kidney damage [ 6]. As the disease progresses, approximately 25% of patients develop lumbar pain, and 15% experience gross hematuria [10]. Histological biopsy and pathological confirmation remain the gold standards for diagnosing UE. Initial evaluation involves a detailed medical history, physical examination, and auxiliary tests. Currently, transvaginal ultrasonography (TVS) combined with urinary system ultrasound is considered a first-line imaging modality for diagnosing DIE because of its noninvasive nature, afford - ability, and reproducibility [ 11, 12]. In cases of hydrone - phrosis, further pelvic MRI and CT imaging can pinpoint the site and severity of ureteral obstruction, whereas renal scintigraphy can be used to assess kidney function [13]. The choice of treatment for UE depends on the patient’s age, fertility intentions, extent of ureteral involvement, and renal function. Surgery is currently considered the gold standard for treating UE. Its main goals are to completely excise endometriotic lesions, relieve ureteral obstruction, and preserve renal function. The second - ary goals include obtaining a pathological diagnosis, enabling long-term management to prevent recurrence and ureteral restenosis [ 14]. Some researchers believe that ureteral stenosis in UE patients is caused primarily by fibrosis and suggest that, even in patients with hydro - nephrosis, ureterolysis alone is effective for most patients and should be considered a fundamental treatment

for UE [15]. In this case, the patient developed lumbar pain more than a year after undergoing total hysterectomy for ade - nomyosis. Considering the patient’s history of adenomyo- sis, a multidisciplinary consultation with the Gynecology Department led to a diagnosis of ureteral endometriosis. The patient subsequently underwent laparoscopic exci - sion of the deep ureteral endometriosis and ureterolysis. Postoperative recovery was uneventful. Timely diagnosis and intervention prevent further complications, such as renal failure. For patients with UE, surgery remains the corner - stone of treatment. However, postoperative recurrence continues to pose a major clinical challenge. Delay - ing or reducing recurrence is a critical objective in the long-term management of endometriosis. Several stud - ies have shown that combining postoperative hormonal Table 1 Chronological summary of diagnosis and treatment Date Clinical Presentation Surgery Date Procedure Department Outcome 2023-03-12 Dysmenorrhea, heavy men- strual bleeding 2023-03-24 Laparoscopic total hysterectomy + bilat- eral salpingectomy + pelvic adhesiolysis Gynecology Recovered and discharged 2024-04-25 Right-sided lumbar pain 2024-04-28 Right ureteral biopsy + transurethral right ureteral stent placement Urology Recovered and discharged 2024-07-12 CT: Soft tissue nodule in lower right ureter near bladder entrance, suspected ureteral endometriosis 2024-07-15 Laparoscopic excision of deep endome- triosis + right ureterolysis + bladder repair Gynecology Postoperative GnRH-a therapy initiated (gos- erelin 3.6 mg every 28 days, total of 6 doses) 2024-08-15 Removal of ureteral stent 2024-08-15 Right ureteral stent removal Urology (Outpatient) Recovered Fig. 3 a Pathological examination (HE staining x200) b Immunohistochemical ER (+) c Immunohistochemical PR (+) Page 5 of 7 Lu and Wang BMC Urology (2025) 25:164 therapy (e.g., GnRH agonists) with surgical treatment sig- nificantly reduces the recurrence rate of UE compared to surgery alone [ 16– 18]. In a study by Di Maida et al., the recurrence rate in the conservative surgery group with - out postoperative hormonal therapy reached as high as 28.6%, highlighting the importance of medical interven - tion, particularly in patients with incompletely excised lesions [ 19]. Similarly, a retrospective study by Cecca - roni et al. involving 160 patients emphasized that radical lesion excision is a key factor in preventing UE recur - rence [20]. These findings, along with others in the literature, are summarized in Table 2. The table provides a comparative overview of reported UE case series, including sample size, surgical methods, use of postoperative hormonal therapy, and recurrence outcomes. It reinforces the importance of individualized treatment strategies and highlights how factors such as surgical completeness, patient age, and autoimmune status contribute to recur - rence risk. Therefore, regardless of the surgical technique used, efforts should be made to ensure complete excision of ectopic lesions, and postoperative hormonal therapy should be considered based on individual risk profiles. In the present case, the lesion was completely excised intraoperatively, and the patient received six months of postoperative GnRH agonist therapy. No recurrence has been observed during follow-up, aligning with the litera - ture’s recommendations for individualized postoperative management in high-risk patients. This case raises the question of whether patients with adenomyosis should receive long-term pharmacological management after definitive hysterectomy to reduce the recurrence rate of endometriosis. Total hysterectomy is the definitive treatment for AM in women who no lon - ger desire fertility. However, there is currently no clear consensus on whether hormonal therapy is necessary following hysterectomy, especially in the absence of vis - ible endometriotic lesions. In clinical practice, postop - erative management varies significantly, and cases like the one presented here raise important questions about whether a more individualized, risk-based approach may be warranted. The necessity of postoperative hormonal therapy fol - lowing hysterectomy for adenomyosis remains a topic of debate. Several studies have demonstrated that adeno - myosis shares estrogen-dependent pathophysiological mechanisms with endometriosis. Thus, even after hys - terectomy, residual endometriotic foci may continue to progress under the influence of endogenous estrogen. For patients undergoing uterus-sparing surgery for AM, postoperative management of endometriosis, or excision of deep infiltrating lesions (DIE), long-term hormonal therapy is commonly recommended to reduce recurrence rates and delay disease progression [21, 22]. However, opposing viewpoints exist: in patients with - out visible lesions or in whom lesions have been com - pletely excised, postoperative hormonal therapy may represent overtreatment. In premenopausal women, such therapy may also induce menopausal side effects, includ - ing hot flashes and decreased bone density [23]. Endometriosis is associated with a relatively high post - operative recurrence rate, with an average 5-year recur - rence of up to 50% [ 24]. Several studies have explored risk factors for recurrence. For example, Seo et al. found that patients aged 40–45 years had significantly lower recurrence rates compared to those under 40, potentially due to lower ovarian activity and estrogen levels, which Table 2 Comparative summary of reported UE cases and recurrence management Study (Au- thor, Year) Sam- ple Size (n) Time to Diagnosis Surgical Approach Postoperative Hormonal Therapy Re- cur- rence Rate Follow-up Duration Key Findings/Notes Jia et al., 2022 [16] 28 Median: 17.8 months Laparoscopic ure- terolysis ± ureteral reimplantation 19 patients received GnRH-a (3–6 months)and 5 patients Gestrinone (3–6 months) 0% 5-72months Emphasized individual- ized treatment approach Liu et al., 2019 [17] 16 Mean: 8.3 ± 2.7 months Laparoscopic ureteroly- sis ± excision ± ureteral reimplantation 15 patients received GnRH-a (4–6 months) 0% 3-24months Confirmed safety and efficacy of laparoscopy in UE Hung et al., 2020 [18] Case series Median: 27.8 months Robot-assisted ureteral reconstruction All patients received GnRH-a (4–6 months) 0% 12-31months Robotic surgery feasible for ureteral reconstruction Di Maida et al., 2022 [19] 105 Not specified Open surgical Approach (24 cases), laparo-Scopic (30 cases), robot-assisted approach(51cases) 52 patients received no hormonal therapy 28.6% 22–51 months Recurrence linked to absence of hormonal therapy, age, autoim- munity, and incomplete resection Ceccaroni et al., 2019 [20] 160 Not specified Laparoscopic ureteroneocystostomy 119patients received post- operative hormone therapy with oral progestin or com- bined estrogen-progestin 1.2% 1–60 months Radical excision essential to reduce recurrence risk Page 6 of 7 Lu and Wang BMC Urology (2025) 25:164 reduce the stimulation of residual endometriotic lesions [25, 26]. In addition, the severity of dysmenorrhea prior to surgery is positively associated with recurrence risk, with more severe pain indicating a higher likelihood of recurrence [27, 28]. A high American Society for Repro - ductive Medicine (ASRM) score, particularly ≥ 40, is also considered a significant risk factor [ 29, 30]. For such patients, meticulous intraoperative exploration and com - plete excision of lesions, combined with postoperative adjuvant hormonal therapy, may help reduce recurrence and improve outcomes. Incomplete excision of deep infiltrating endometriosis (DIE) lesions is another key contributor to recurrence [31]. Due to the extensive and dense adhesions com - monly seen in DIE, surgical planning should aim to pre - serve pelvic nerves in order to avoid iatrogenic injury and minimize postoperative pelvic organ dysfunction. Recent studies suggest that nerve-sparing surgical approaches can significantly improve postoperative pelvic organ function, particularly urinary and bowel function [32]. In light of this literature, we hypothesize that the absence of postoperative hormonal therapy in this case may have contributed to the development of ureteral endometriosis. We propose that a risk-stratified man - agement approach may be beneficial. Patients with fac - tors such as age < 40, intraoperative DIE involvement, suspected residual lesions, or severe symptoms may still require postoperative hormonal therapy, even after total hysterectomy, to prevent recurrence in deep pelvic organs. Conversely, for patients without high-risk fea - tures and with complete lesion excision, close monitoring may be a reasonable alternative to routine pharmacologi - cal intervention.

This case highlights a potential need to re-evaluate the role of long-term hormonal therapy in patients with adenomyosis who undergo total hysterectomy, par - ticularly in preventing deep infiltrating recurrence such as ureteral endometriosis. While causality cannot be established from a single case, this observation supports further investigation into risk-stratified postoperative management strategies. Additional clinical studies are warranted to clarify patient subgroups who may benefit from continued pharmacological therapy despite defini - tive surgery. Patient perspective The patient reported satisfaction with the overall treat - ment process and was pleased with the improvement in her symptoms following surgery and hormonal therapy. She expressed gratitude for the timely diagnosis and mul- tidisciplinary care provided. Abbreviations AM Adenomyosis EM Endometriosis UE Ureteral endometriosis DIE Deep infiltrating endometriosis GnRH-a Gonadotropin-releasing hormone agonist ASRM American Society for Reproductive Medicine Supplementary Information The online version contains supplementary material available at h t t p s : / / d o i . o r g / 1 0 . 1 1 8 6 / s 1 2 8 9 4 - 0 2 5 - 0 1 8 6 6 - 9. Supplementary Material 1.

Not applicable. Authors’ contributions Yujuan Lu wrote the main manuscript, Yu Wang prepared Figs. 1, 2 and 3. All authors reviewed the manuscript. Funding No funding. Data availability Data is provided within the manuscript or supplementary information files. Declarations Ethics approval and consent to participate Ethics approval and consent to participate Consent for publication The patient gave written informed consent for her personal or clinical details along with any identifying images to be published in this study. Competing interests The authors declare no competing interests. Received: 8 January 2025 / Accepted: 26 June 2025

1. Falcone T, Flyckt R. Clinical management of endometrio-sis. Obstet Gynecol. 2018;131(3):557–71. 2. Vercellini P , Viganò P , Somigliana E, et al. Adenomyosis:epidemio⁃ logical fac- tors. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):465–77. 3. Bourdon M, Santulli P , Marcellin L, et al. Adenomyo- sis: an update regard- ing its diagnosis and clinical features. J Gynecol Obstet Hum Reprod. 2021;50(10):102228. 4. Wahl KJ, Orr NL, Lisonek M, et al. Deep dyspareunia, superficial dyspareunia, and infertility concerns among women with endometriosis:a cross-sectional study. Sex Med. 2020;8(2):274–81. 5. Raimondo D, Raffone A, Renzulli F, et al. Prevalence and risk factors of central sensitization in women with endometriosis. J Minim Invasive Gynecol. 2023;30(1):74–80. 6. Berlanda N, Vercellini P , Carmignani L, et al. Ureteral and vesical endome- triosis. Two different clinical entities sharing the same pathogenesis. Obstet Gynecol Surv. 2009;64(12):830–42. 7. Barra F, Scala C, Biscaldi E, et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transfor- mation and fertility. Hum Reprod Update. 2018;24(6):710–30. 8. Seracchioli R, Raimondo D, Di Donato N, et al. Histological evaluation of ureteral involvement in women with deep infiltrating endometriosis: analysis of a large series. Hum Reprod. 2015;30(4):833–9. Page 7 of 7 Lu and Wang BMC Urology (2025) 25:164 9. Huang JZ, Guo HL, Li JB, et al. Management of ureter-al endometriosis with hydronephrosis: experience from a tertiary medical center. J Obstet Gynaecol Res. 2017;43(10):1555–62. 10. Spagnolo E, Hernández A, Pascual I, et al. Bowel and ureteral assessment by indocyanine green real-time visualization during deep infiltrating endome- triosis surgery: a video vignette. Colorectal Dis. 2020;22(10):1464–5. 11. Carfagna P , Decicco Nardone C, Decicco Nardone A, et al. Role of transvaginal ultrasound in evaluation of ureteral involvement in deep infiltrating endome- triosis. Wiley Ultrasound Obstet Gynecol. 2018;51(4):550–5. 12. Guerriero S, Condous G, Vandenbosch T, et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endome- triosis, including terms, definitions and measurements: a consensus opinion from the international deep endometriosis analysis (IDEA) group. Ultrasound Obstet Gynecol. 2016;48(3):318–32. 13. Wang LM, Sun S, An R, et al. Clinical diagnosis and treatment analysis of ureteral endometriosis. Chin J Clin Obstet Gynecol. 2020;21(3):299–301. 14. Kızılay F, Şimşir A, Nazlı O. Management of ureteral endometriosis and review of the literature. 2018. pp. 166–169. 15. Philip CA, Froc E, Chapron C, et al. Surgical management of urinary tract endometriosis: A1-year Longitudinal multicenter pilot study at 31 French Hospitals (by the FRIENDS Group). J Minim Invasive Gynecol. 2021;28(11):1889–97. 16. Jia Z, Yan-Ni. "Diagnosis and treatment of ureteral endometriosis: an analysis of 28 cases." Master,s thesis, Shanxi Medical University; 2022. CNKI. h t t p s : / / w w w . c n k i . n e t . 17. Liu Q, Sun YX, Liu KJ, et al. Analysis of the diagnosis and treatment of ureteral endometriosis by laparoscopic surgery in 16 patients. Chin J Pract Gynecol Obstet. 2019;35(8):934–937. 18. Hung ZC, Hsu TH, Jiang LY, et al. Robot-assisted laparoscopic ureteral recon- struction for ureter endometriosis: case series and literature review. J Chin Med Assoc. 2020;83(3):288–294. 19. Di Maida F, Lambertini L, Grosso AA, et al. Urinary tract endometriosis: how to predict and prevent recurrence after primary surgical excision. J Minim Invasive Gynecol. 2022;29(10):1178–1183. 20. CeccaroniM CM, Caleffi G, et al. Total laparoscopic ureteroneocystostomy for ureteral endometriosis: a single-center experience of 160 consecutive patients. J Minim Invasive Gynecol. 2019;26(1):78–86. 21. Bedaiwy MA, Allaire C, Alfaraj S. Long-term medical management of endome- triosis with dienogest and with a gonadotropin-releasing hormone agonist and add- back hormone therapy. Fertil Steril. 2017;107:537–48. 22. Zheng H, Qi XR. Interpretation of the ESHRE endometriosis management guidelines. Chin J Fam Plann Gynecol. 2023;15(8):3–7. 23. Seo JW, Lee DY, Kim SE, et al. Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery. Eur J Obstet Gynecol Reprod Biol. 2019;236:53–7. 24. Ceccaroni M, Bounous VE, Clarizia R, et al. Recurrent endometriosis:a battle against an unknown enemy. Eur J Contracept Reprod Health Care. 2019;24(6):464–74. 25. Seo JW, Lee DY, Yoon BK, et al. The age-related recurrence of endometrioma after conservative surgery. Eur J Obstet Gynecol Reprod Biol. 2017;208:81–5. 26. Yang F, Liu B, Xu L, et al. Age at surgery and recurrence of ovarian endome- trioma after conservative surgery: a meta-analysis including 3125 patients. Arch Gynecol Obstet. 2020;302:23–30. 27. Tobiume T, Kotani Y, Takaya H, et al. Determinant factors of postoperative recurrence of endometriosis: difference between endometrioma and pain. Eur J Obstet Gynecol Reprod Biol. 2016;205:54–9. 28. Hu LH, Chen Y, Zhou Y, et al. Risk factors for recurrence after laparoscopic conservative surgery in patients with stage III-IV endometriosis. J Int Obstet Gynecol. 2021;48(3):314–317. 29. Coccia ME, Rizzello F, Palagiano A, et al. Long-term follow-up after laparo- scopic treatment for endometriosis: multivariate analysis of predictive factors for recurrence of endometriotic lesions and pain. Eur J Obstet Gynecol Reprod Biol. 2011;157:78–83. 30. Kikuchi I, Takeuchi H, Kitade M, et al. Recurrence rate of endometrio- mas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand. 2006;85(9):1120–1124.  31. Yela DA, Vitale SG, Vizotto MP , et al. Risk factors for recurrence of deep infiltrating endometriosis after surgical treatment. J Obstet Gynaecol Res. 2021;47(8):2713–2719.  32. Manuel MI, Diego R, Andrea R, et al. Impact of nerve- sparing posterolateral parametrial excision for deep infiltrating endometriosis on postoperative bowel, urinary, and sexual function. Int J Gynecol Obstet. 2022;159:152–159. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.